SLC16A1 and breast cancer: Treatment of high malignant T24 and UMUC-3 with MCT1 inhibitor AR-C155858 which blocks lactate export 68 results in a reduction of invasiveness that is dose-dependent (Figure 2F,G and Figure S1F,G), supporting recent findings in other BC cell lines 69.